Stay Informed With Our Latest Updates

Client Alert August 11, 2026

FDA Proposes Mandatory GRAS Notification for Food Substances, with a Time-Limited Streamlined Path

FDA has proposed converting its voluntary notification program for substances in food that are generally recognized as safe (GRAS) into a mandatory one, with a one-year window for streamlined submissions for food substances already on the market. If the GRAS notification requirement is not met, FDA intends to consider noncompliance as a factor in its prioritization of food substances for post-market review.

Webcasts May 7, 2026

Webcast: Meat and Poultry Industry Enforcement Outlook: Recalls, Investigations, and Regulatory Shifts

Recent outbreaks, shifting regulatory priorities, and continued White House scrutiny of the food supply chain are reshaping how regulators approach …

Client Alert April 29, 2026

DEA Downschedules State Medical Marijuana to Schedule III; Expedited Hearing Set to Consider Broader Rescheduling

A Drug Enforcement Administration final order moves (1) marijuana contained in a Food and Drug Administration-approved drug product and (2) …

Client Alert January 15, 2026

The Year Ahead for Food and Beverage: Key Litigation, Regulatory, and Transactional Trends for 2026

Gibson Dunn’s Consumer Products and Retail team highlights several of the most significant legal trends we expect to shape litigation, regulatory compliance, and dealmaking for food and beverage companies in the year ahead.

Client Alert January 12, 2026

HHS and USDA Publish Updated Dietary Guidelines for Americans – What You Need to Know

The new Dietary Guidelines are described by USDA and HHS as marking “the most significant reset of federal nutrition policy in our nation’s history” and include several notable changes from prior editions.

Client Alert January 12, 2026

Life Sciences 2026 Outlook

The life sciences industry enters 2026 with a constructive set of tailwinds, following a second half of 2025 in which dealmaking activity showed clearer signs of normalization after a prolonged slowdown. While risks remain, particularly around geopolitics, trade policy, and regulatory priorities, the overall setup for 2026 is cautiously constructive, with improved visibility into execution pathways for well-positioned assets and platforms.

Royalty Finance Tracker

The Gibson Dunn team has represented clients in royalty finance transactions with a total aggregate value of approximately $8 Billion.

Firm News November 14, 2025

Gibson Dunn Advising Merck on $9.2 Billion Acquisition of Cidara Therapeutics

Gibson Dunn is advising Merck on its $9.2 billion acquisition of Cidara Therapeutics, Inc., a biotechnology company developing drug-Fc conjugate (DFC) therapeutics